A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia. Escalating vosaroxin doses (10-minute infusion;...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Lancet, Jeffrey E., Roboz, Gail J., Cripe, Larry D., Michelson, Glenn C., Fox, Judith A., Leavitt, Richard D., Chen, Tianling, Hawtin, Rachael, Craig, Adam R., Ravandi, Farhad, Maris, Michael B., Stuart, Robert K., Karp, Judith E.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803139/
https://ncbi.nlm.nih.gov/pubmed/25381131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.114769
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados